On Tuesday, Dr.Reddy’s Laboratories Ltd (ADR)(NYSE:RDY)’s shares inclined 2.06% to $65.84.
Dr. Reddy’s Laboratories (RDY) declared recently that it has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic version of MIRAPEX ER® (pramipexole dihydrochloride) Extended-Release Tablets in the US market on August 11, 2015, following the approval by the United States Food & Drug Administration (USFDA).
The MIRAPEX ER® brand and generic had U.S. sales of about $48.3 Million MAT for the most recent twelve months ending in June 2015 according to IMS Health*.
Dr. Reddy’s PRAMIPEXOLE dihydrochloride extended-release tablets mg are accessible in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.
Dr. Ready’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages.
MiMedx Group Inc(NASDAQ:MDXG)’s shares dropped -0.51% to $9.76.
MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, declared recently that its latest peer-reviewed scientific study, “Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro,” was electronically published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
The electronic publication of the peer-reviewed article is now accessible in the Wiley Online Library and can be found at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33478/abstract. The paper was authored by Michelle Massee; Kathryn Chinn; Jennifer Lei; Jeremy J. Lim, PhD; Conan S. Young, PhD; and Thomas J. Koob, PhD. The hard copy publication is predictable to follow in a future issue of the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
At the end of Tuesday’s trade, Golar LNG Limited (USA)(NASDAQ:GLNG)‘s shares surged 0.48% to $39.37.
Golar LNG Limited declared that it has executed agreements for conversion of the 126,000 m3 LNG carrier Gandria to a Golar floating liquefaction facility (“GoFLNG”). As with the GoFLNG Hilli and Gimi conversions, the primary contract for the GoFLNG Gandria was reached with Singapore’s Keppel Shipyard Limited (“Keppel”). The Gandria conversion contract marks the exercise of the second of two options that formed part of the initial 2014 Hilli conversion contract. Black & Veatch will provide its licensed PRICO(R) technology, perform detailed engineering and process design, specify and procure topside equipment, and provide commissioning support for the GoFLNG topsides and liquefaction process.
The decision to go ahead with the third conversion project was taken following a thorough review of the growing portfolio of business development opportunities for GoFLNG. This has shown potential demand from several possible customers for delivery of floating liquefaction facilities as early as 2018. In order to respond to this potential, the Gandria conversion will now be dedicated to satisfy the commitments to Ophir in Equatorial Guinea, covered by the agreement declared in May this year, requiring delivery of GoFLNG facilities in 2019. In parallel with this decision to commit Gandria to the Ophir project, Keppel and Black & Veatch will now update their FEED study, accommodating the deep water operation in Equatorial Guinea on the basis of Gandria. This move will release the Gimi to cover the potential emerging demand for a 2018 GoFLNG project. Provisions in the Gimi and Gandria contracts provide Golar the flexibility to adjust project timing and to limit expenditure to front-end engineering activities and long-lead equipment cancellation charges should timing and scope of predictable or potential projects change.
Golar LNG Limited, a midstream liquefied natural gas (LNG) company, engages in the transportation, regasification, liquefaction, and trading of LNG. The company operates in three segments: Vessel Operations, LNG Trading, and FLNG.
TransUnion(NYSE:TRU), ended its Tuesday’s trading session with -3.81% loss, and closed at $25.73.
A new TransUnion (TRU) survey found that the number of properties one manages impacts which traits are used for evaluating prospective residents. Six in 10 (60.4%) small property managers ranked income and employment information as the most important factor. Seven in 10 (70%) large property managers ranked rental and eviction history as the most important tool for screening residents.
Both small (those persons managing 100 units or less) and large (those persons managing 101 or more units) property managers ranked criminal and background checks as the third most important factor, and credit history as the least important factor.
TransUnion provides risk and information solutions in the United States and internationally. The company operates in three segments: U.S. Information Services, International, and Consumer Interactive segments. The U.S. Information Services segment provides consumer reports, risk scores, analytical services, and decisioning capabilities; and online data, marketing, and decision services. Its services are used to acquire new customers; assess consumer ability to pay for services; identify cross-selling opportunities; measure and manage debt portfolio risk; collect debt; verify consumer identities; and investigate potential fraud.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
